Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients : another COVID-19 paradox?
© 2021. Springer Science+Business Media, LLC, part of Springer Nature..
Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured total levels of von Willebrand factor (vWF) and vWF binding to the platelet glycoprotein (Gp) complex (GPIb-IX-V), in a cohort of COVID-19 patients admitted to the intensive care unit of our Institution. Moreover, we evaluated platelet aggregation in response to agonists (ADP, collagen, arachidonic acid) and platelet agglutination in response to ristocetin. We found that levels of vWF antigen and the active form of vWF binding to platelets (vWF:RCo), were markedly increased in these patients. These results were associated with higher agglutination rates induced by ristocetin, thereby indirectly indicating an increased capability of vWF to bind to platelets. Conversely, we found that platelet aggregation in response to both ADP and collagen was lower in COVID-19 patients compared to healthy volunteers. This study shows that COVID-19 is associated with increased vWF-induced platelet agglutination but reduced platelet responsivity to aggregation stimuli. Our findings have translational relevance since platelet adhesion to vWF may represent a marker to predict possible complications and better delineate therapeutic strategies in COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Journal of thrombosis and thrombolysis - 52(2021), 1 vom: 02. Juli, Seite 105-110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruberto, Franco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Covid 19 |
|---|
| Anmerkungen: |
Date Completed 21.07.2021 Date Revised 18.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11239-020-02339-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319512312 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319512312 | ||
| 003 | DE-627 | ||
| 005 | 20231225171616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11239-020-02339-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319512312 | ||
| 035 | |a (NLM)33387210 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruberto, Franco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients |b another COVID-19 paradox? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2021 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured total levels of von Willebrand factor (vWF) and vWF binding to the platelet glycoprotein (Gp) complex (GPIb-IX-V), in a cohort of COVID-19 patients admitted to the intensive care unit of our Institution. Moreover, we evaluated platelet aggregation in response to agonists (ADP, collagen, arachidonic acid) and platelet agglutination in response to ristocetin. We found that levels of vWF antigen and the active form of vWF binding to platelets (vWF:RCo), were markedly increased in these patients. These results were associated with higher agglutination rates induced by ristocetin, thereby indirectly indicating an increased capability of vWF to bind to platelets. Conversely, we found that platelet aggregation in response to both ADP and collagen was lower in COVID-19 patients compared to healthy volunteers. This study shows that COVID-19 is associated with increased vWF-induced platelet agglutination but reduced platelet responsivity to aggregation stimuli. Our findings have translational relevance since platelet adhesion to vWF may represent a marker to predict possible complications and better delineate therapeutic strategies in COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Covid 19 | |
| 650 | 4 | |a Platelets | |
| 650 | 4 | |a vonWillebrand factor | |
| 650 | 7 | |a von Willebrand Factor |2 NLM | |
| 700 | 1 | |a Chistolini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Curreli, Mariaignazia |e verfasserin |4 aut | |
| 700 | 1 | |a Frati, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Marullo, Antonino G M |e verfasserin |4 aut | |
| 700 | 1 | |a Biondi-Zoccai, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Mancone, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Sciarretta, Sebastiano |e verfasserin |4 aut | |
| 700 | 1 | |a Miraldi, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Alessandri, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Barone, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Alvaro, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Pulcinelli, Fabio M |e verfasserin |4 aut | |
| 700 | 0 | |a Policlinico Umberto I COVID-19 Group |e verfasserin |4 aut | |
| 700 | 1 | |a Albante, Alida |e investigator |4 oth | |
| 700 | 1 | |a Alessandri, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Alvaro, Domenico |e investigator |4 oth | |
| 700 | 1 | |a Antonelli, Guido |e investigator |4 oth | |
| 700 | 1 | |a Araimo-Morselli, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Auricchio, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Barone, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Bilotta, Federico |e investigator |4 oth | |
| 700 | 1 | |a Brisciani, Giuseppe Biondi-Zoccai Matteo |e investigator |4 oth | |
| 700 | 1 | |a Bruno, Katia |e investigator |4 oth | |
| 700 | 1 | |a Cappannoli, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Cardinale, Vincenzo |e investigator |4 oth | |
| 700 | 1 | |a Ceccarelli, Giancarlo |e investigator |4 oth | |
| 700 | 1 | |a Celli, Paola |e investigator |4 oth | |
| 700 | 1 | |a Chistolini, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Consolo, Stella |e investigator |4 oth | |
| 700 | 1 | |a Croce, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Crocitti, Beatrice |e investigator |4 oth | |
| 700 | 1 | |a Curreli, Mariaignazia |e investigator |4 oth | |
| 700 | 1 | |a D'Ettorre, Gabriella |e investigator |4 oth | |
| 700 | 1 | |a De Daniela, Lauri |e investigator |4 oth | |
| 700 | 1 | |a De Lazzaro, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Fedele, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Frati, Giacomo |e investigator |4 oth | |
| 700 | 1 | |a Galardo, Gioacchino |e investigator |4 oth | |
| 700 | 1 | |a Giannetti, Lorena |e investigator |4 oth | |
| 700 | 1 | |a Ianni, Stefano |e investigator |4 oth | |
| 700 | 1 | |a Imperiale, Carmela |e investigator |4 oth | |
| 700 | 1 | |a Maestrini, Viviana |e investigator |4 oth | |
| 700 | 1 | |a Magnanimi, Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Maldarelli, Federica |e investigator |4 oth | |
| 700 | 1 | |a Mancone, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Martelli, Sabina |e investigator |4 oth | |
| 700 | 1 | |a Marullo, Antonino G M |e investigator |4 oth | |
| 700 | 1 | |a Mastroianni, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Messina, Teresa |e investigator |4 oth | |
| 700 | 1 | |a Miraldi, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Pattelli, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Pecorari, Filippo |e investigator |4 oth | |
| 700 | 1 | |a Perrella, Serena |e investigator |4 oth | |
| 700 | 1 | |a Piazzolla, Mario |e investigator |4 oth | |
| 700 | 1 | |a Portieri, Monica |e investigator |4 oth | |
| 700 | 1 | |a Pugliese, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Pulcinelli, Fabio M |e investigator |4 oth | |
| 700 | 1 | |a Ratini, Fabiola |e investigator |4 oth | |
| 700 | 1 | |a Ricci, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Ruberto, Franco |e investigator |4 oth | |
| 700 | 1 | |a Santopietro, Pietro |e investigator |4 oth | |
| 700 | 1 | |a Tellan, Guglielmo |e investigator |4 oth | |
| 700 | 1 | |a Titi, Luca |e investigator |4 oth | |
| 700 | 1 | |a Tordiglione, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Tosi, Antonella |e investigator |4 oth | |
| 700 | 1 | |a Trigilia, Fausto |e investigator |4 oth | |
| 700 | 1 | |a Santoro, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Sciarretta, Sebastiano |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thrombosis and thrombolysis |d 1994 |g 52(2021), 1 vom: 02. Juli, Seite 105-110 |w (DE-627)NLM094439990 |x 1573-742X |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2021 |g number:1 |g day:02 |g month:07 |g pages:105-110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11239-020-02339-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2021 |e 1 |b 02 |c 07 |h 105-110 | ||